ArticleFrontiers in pharmacology2026
Patterns and determinants of drug-drug interactions among community-dwelling older adults in Saudi Arabia: a cross-sectional study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polypharmacy is increasingly common among older adults due to the high prevalence of chronic conditions, contributing to a greater risk of potential drug-drug interactions (DDIs). However, limited evidence exists on the patterns and risk factors of DDIs in community-dwelling older adults in Saudi Arabia. This study investigated the patterns, and determinants of DDIs among older outpatients. Methods: A cross-sectional study was conducted between November 2024 and March 2025, targeting patients aged ≥60 years. Data were collected through structured face-to-face interviews. Potential DDIs were identified using Stockley's Drug Interactions database. Descriptive statistics were used to characterize DDI prevalence, severity, and drug pairs. A Results: A total of 285 potential DDIs were identified among 173 participants, with 67.2% experiencing at least one interaction. Potential DDIs classified as moderate and severe accounted for 69.1% and 23.2% of cases, respectively. Amlodipine, aspirin, and insulin were the most commonly implicated medications, while atorvastatin, perindopril, and gliclazide were frequently involved in severe interactions. Polypharmacy (≥5 medications) was significantly associated with both overall (aOR = 10.50; 95% CI: 2.02-54.64) and potential severe DDIs (aOR = 14.33; 95% CI: 3.84-53.55). Hypertension was significantly associated with an increased likelihood of overall potential DDIs (aOR = 4.81; 95% CI: 2.10-11.03) and potential severe DDIs (aOR = 6.81; 95% CI: 2.25-20.66). Conclusion: Potential DDIs are common among older outpatients in Saudi Arabia, particularly among those with hypertension and higher medication burden. Although many interactions were classified as moderate or severe, most required monitoring rather than therapy modification, and their clinical relevance may vary depending on dosage and treatment context. Routine DDI screening and pharmacist-led medication review may enhance medication safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.